Trials / Completed
CompletedNCT01473251
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Vitreo-Retinal Associates, Michigan · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avastin | 1.25 mg monthly for 4 months |
| DRUG | Avastin | 1.25 mg monthly for 4 months |
| DRUG | Lucentis | 0.5 mg monthly for 4 months |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2011-11-17
- Last updated
- 2014-12-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01473251. Inclusion in this directory is not an endorsement.